Genital Herpes

Positive Results with Cidofovir Announced - More PMPA Data Needed

Published in AIDS Weekly, June 10th, 1996

Gilead Sciences, Foster City, California, announced that data from a placebo-controlled Phase I/II study of single-dose cidofovir topical gel in immunocompetent patients with recurrent genital herpes lesions showed significant evidence of antiviral activity.

"These preliminary data provide clear evidence of an antiviral effect in patients with recurrent genital herpes," said Dr. Stephen L. Sacks, Viridae Clinical Sciences, Vancouver, British Columbia. "These are very promising results that warrant further study."

Based on the data, Gilead said it has planned to move ahead with Phase II/II studies of cidofovir for the treatment of recurrent genital...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry